Biotech Values

[ghmm]

This really shouldn't have come as a big suprise to anyone who follows the company. It was clear InterMune was going to do deal the question was just when, what if any part they'd keep and how much they'd get (even that one could make a good educated guess).

http://www.investorshub.com/boards/read_msg.asp?message_id=13924302

I don't think it is too rich an price. You need to balance they are late (3rd PI) vs. potential better safety, efficacy and maybe dosing. I think InterMune being in a cash burn situation wasn't going to do a deal with at least some up-front cash.